3Bruera E,Sala R,Spruyt O,et al.Nebulized versus subcutaneous morphine for patients with cancer dyspnea:a preliminary study.J Pain Symptom Manage,2005; 29(6):613-618.
4Zebraski SE,Kochenash SM,Raffa RB.Lung opioid receptors:pharmacology and possible target for nebulized morphine in dyspnea.Life Sci,2000; 66(23):2221-2231.
5Elsasser S,Perruchoud AP.The treatment of terminal dyspnea.Schweiz Rundsch Med Prax,1992; 81(1-2):11-14.
6Thomas JR,yon Gunten CF.Clinical management of dyspnoea.Lancet Oncol,2002; 3(4):223-228.
7Navigante AH,Cerchietti LC,Castro MA,et al.Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.J Pain Symptom Manage,2006;31(1):38-47.
8Bruera E,de Stoutz N,Velasco-Leiva A,et al.Effects of oxygen on dyspnoea in hypoxaemicterminal-cancer patients.Lancet,1993;342(8862):13-14.
9Bruera E,Schoeller T,MacEachern T.Symptomaticbenefit of supplemental oxygen in hypoxemicpatients with terminal cancer:the use of the N of 1 randomized controlled trial.J Pain Symptom Manage,1992; 7(6):365-368.
10Bruera E,Sweeney C,Willey J,et al.A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea.Palliat Med,2003; 17(8):659-663.
